Go to
JCI Insight
Citations to this article
Silvia Pozzi, … , Claude Gravel, Jean-Pierre Julien
Published January 22, 2019
Citation Information: J Clin Invest. 2019;129(4):1581-1595. https://doi.org/10.1172/JCI123931.
Citation Information: J Clin Invest. 2019;129(4):1581-1595. https://doi.org/10.1172/JCI123931.
Abstract
The cytoplasmic aggregation of TAR DNA-binding protein-43 (TDP-43) is a hallmark of degenerating neurons in amyotrophic lateral sclerosis (ALS) and subsets of frontotemporal dementia (FTD). In order to reduce TDP-43 pathology, we generated single-chain (scFv) antibodies against the RNA recognition motif 1 (RRM1) of TDP-43, which is involved in abnormal protein self-aggregation and interaction with p65 NF-κB. Virus-mediated delivery into the nervous system of a scFv antibody, named VH7Vk9, reduced microgliosis in a mouse model of acute neuroinflammation and mitigated cognitive impairment, motor defects, TDP-43 proteinopathy, and neuroinflammation in transgenic mice expressing ALS-linked TDP-43 mutations. These results suggest that antibodies targeting the RRM1 domain of TDP-43 might provide new therapeutic avenues for the treatment of ALS and FTD.
Authors
Silvia Pozzi, Sai Sampath Thammisetty, Philippe Codron, Reza Rahimian, Karine Valérie Plourde, Geneviève Soucy, Christine Bareil, Daniel Phaneuf, Jasna Kriz, Claude Gravel, Jean-Pierre Julien
Total citations by year
Citation information
Citations to this article (42)
| Title and authors | Publication | Year |
|---|---|---|
|
Graphene Quantum Dots Attenuate TDP-43 Proteinopathy in Amyotrophic Lateral Sclerosis
Park NY, Heo Y, Yang JW, Yoo JM, Jang HJ, Jo JH, Park SJ, Lin Y, Choi J, Jeon H, Cha SJ, Bae G, Kim D, Kim J, Zeno W, Park JB, Isozumi N, Saio T, Kim SH, Lee H, Hong BH, Nahm M, Lee YH, Hong YB |
ACS Nano | 2025 |
|
Cryptic splicing of stathmin-2 and UNC13A mRNAs is a pathological hallmark of TDP-43-associated Alzheimer's disease.
Agra Almeida Quadros AR, Li Z, Wang X, Ndayambaje IS, Aryal S, Ramesh N, Nolan M, Jayakumar R, Han Y, Stillman H, Aguilar C, Wheeler HJ, Connors T, Lopez-Erauskin J, Baughn MW, Melamed Z, Beccari MS, Olmedo Martínez L, Canori M, Lee CZ, Moran L, Draper I, Kopin AS, Oakley DH, Dickson DW, Cleveland DW, Hyman BT, Das S, Ertekin-Taner N, Lagier-Tourenne C |
Acta Neuropathologica | 2024 |
|
Tryptophan residues in TDP-43 and SOD1 modulate the cross-seeding and toxicity of SOD1
Pokrishevsky E, DuVal MG, McAlary L, Louadi S, Pozzi S, Roman A, Plotkin SS, Dijkstra A, Julien JP, Allison WT, Cashman NR |
The Journal of biological chemistry | 2024 |
|
Protein aggregation and therapeutic strategies in SOD1- and TDP-43- linked ALS
Tsekrekou M, Giannakou M, Papanikolopoulou K, Skretas G |
Frontiers in Molecular Biosciences | 2024 |
|
Mitigation of TDP-43 toxic phenotype by an RGNEF fragment in amyotrophic lateral sclerosis models
Droppelmann CA, Campos-Melo D, Noches V, McLellan C, Szabla R, Lyons TA, Amzil H, Withers B, Kaplanis B, Sonkar KS, Simon A, Buratti E, Junop M, Kramer JM, Strong MJ |
Brain : a journal of neurology | 2024 |
|
CUTS RNA Biosensor for the Real-Time Detection of TDP-43 Loss-of-Function
Xie L, Merjane J, Bergmann CA, Xu J, Hurtle B, Donnelly CJ |
2024 | |
|
A patient-derived amyotrophic lateral sclerosis blood-brain barrier model for focused ultrasound-mediated anti-TDP-43 antibody delivery
Wasielewska JM, Chaves JC, Cabral-da-Silva MC, Pecoraro M, Viljoen SJ, Nguyen TH, Bella VL, Oikari LE, Ooi L, White AR |
Fluids and barriers of the CNS | 2024 |
|
Prion-like Spreading of Disease in TDP-43 Proteinopathies
Pongrácová E, Buratti E, Romano M |
Brain Sciences | 2024 |
|
Sustained therapeutic benefits by transient reduction of TDP-43 using ENA-modified antisense oligonucleotides in ALS/FTD mice
Takeuchi T, Maeta K, Ding X, Oe Y, Takeda A, Inoue M, Nagano S, Fujihara T, Matsuda S, Ishigaki S, Sahashi K, Minakawa EN, Mochizuki H, Neya M, Sobue G, Nagai Y |
2023 | |
|
Disrupting Pathologic Phase Transitions in Neurodegeneration
Bryan T. Hurtle1,2,3,*, Longxin Xie3,4,*, Christopher J Donnelly1,2,3,4,5 |
Journal of Clinical Investigation | 2023 |
|
Recent progress of the genetics of amyotrophic lateral sclerosis and challenges of gene therapy
Wang H, Guan L, Deng M |
Frontiers in neuroscience | 2023 |
|
Targeting the glycine-rich domain of TDP-43 with antibodies prevents its aggregation in vitro and reduces neurofilament levels in vivo
Riemenschneider H, Simonetti F, Sheth U, Katona E, Roth S, Hutten S, Farny D, Michaelsen M, Nuscher B, Schmidt MK, Flatley A, Schepers A, Gruijs da Silva LA, Zhou Q, Klopstock T, Liesz A, Arzberger T, Herms J, Feederle R, Gendron TF, Dormann D, Edbauer D |
Acta Neuropathologica Communications | 2023 |
|
TDP-43 Epigenetic Facets and Their Neurodegenerative Implications
Gimenez J, Spalloni A, Cappelli S, Ciaiola F, Orlando V, Buratti E, Longone P |
International journal of molecular sciences | 2023 |
|
AAV Vector-Mediated Antibody Delivery (A-MAD) in the Central Nervous System
M Marino, M Holt |
Frontiers in neurology | 2022 |
|
Selection and Modelling of a New Single-Domain Intrabody Against TDP-43
M Gilodi, S Lisi, E Dudás, M Fantini, R Puglisi, A Louka, P Marcatili, A Cattaneo, A Pastore |
Frontiers in Molecular Biosciences | 2022 |
|
Approaches to Gene Modulation Therapy for ALS.
Meijboom KE, Brown RH |
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics | 2022 |
|
Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD.
Hayes LR, Kalab P |
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics | 2022 |
|
A Single Chain Fragment Variant Binding Misfolded Alpha-Synuclein Exhibits Neuroprotective and Antigen-Specific Anti-Inflammatory Properties
Fassler M, Benaim C, George J |
Cells | 2022 |
|
Proteostatic imbalance and protein spreading in amyotrophic lateral sclerosis
ME Cicardi, L Marrone, M Azzouz, D Trotti |
The EMBO Journal | 2021 |
|
Gene therapy for ALS: A review
DA Amado, BL Davidson |
Molecular Therapy | 2021 |
|
Astrocytic expression of the Alzheimer’s disease risk allele, ApoEε4, potentiates neuronal tau pathology in multiple preclinical models
AM Jablonski, L Warren, M Usenovic, H Zhou, J Sugam, S Parmentier-Batteur, B Voleti |
Scientific Reports | 2021 |
|
TDP-43 and Inflammation: Implications for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
F Bright, G Chan, A van Hummel, LM Ittner, YD Ke |
International journal of molecular sciences | 2021 |
|
Induction of autophagy mitigates TDP-43 pathology and translational repression of neurofilament mRNAs in mouse models of ALS/FTD
S Kumar, D Phaneuf, P Cordeau, H Boutej, J Kriz, JP Julien |
Molecular Neurodegeneration | 2021 |
|
The Interplay of RNA Binding Proteins, Oxidative Stress and Mitochondrial Dysfunction in ALS
J Harley, BE Clarke, R Patani |
Antioxidants | 2021 |
|
Beyond the Traditional Clinical Trials for Amyotrophic Lateral Sclerosis and The Future Impact of Gene Therapy
M Cappella, PF Pradat, G Querin, MG Biferi |
Journal of neuromuscular diseases | 2021 |
|
Serum naturally occurring anti-TDP-43 auto-antibodies are increased in amyotrophic lateral sclerosis
E Conti, G Sala, S Diamanti, M Casati, C Lunetta, F Gerardi, C Tarlarini, L Mosca, N Riva, Y Falzone, M Filippi, I Appollonio, C Ferrarese, L Tremolizzo |
Scientific Reports | 2021 |
|
Treating Parkinson’s Disease with Antibodies: Previous Studies and Future Directions
AM Castonguay, C Gravel, M Lévesque |
Journal of Parkinson's disease | 2021 |
|
Direct targeting of TDP-43, from small molecules to biologics: the therapeutic landscape
L Francois-Moutal, DD Scott, M Khanna |
2021 | |
|
Antibody-Based Therapeutic Interventions for Amyotrophic Lateral Sclerosis: A Systematic Literature Review
A Poulin-Brière, E Rezaei, S Pozzi |
Frontiers in neuroscience | 2021 |
|
Monoclonal full-length antibody against TAR DNA binding protein 43 reduces related proteinopathy in neurons
Silvia Pozzi, Philippe Codron, Genevieve Soucy, Laurence Renaud, Pierre Cordeau, Kallol Dutta, Christine Bareil, Jean-Pierre Julien |
JCI Insight | 2020 |
|
Transmission of ALS pathogenesis by the cerebrospinal fluid
PS Mishra, H Boutej, G Soucy, C Bareil, S Kumar, V Picher-Martel, N Dupré, J Kriz, JP Julien |
Acta Neuropathologica Communications | 2020 |
|
Dysregulation of RNA-Binding Proteins in Amyotrophic Lateral Sclerosis
YC Xue, CS Ng, P Xiang, H Liu, K Zhang, Y Mohamud, H Luo |
Frontiers in molecular neuroscience | 2020 |
|
Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets
S Kwon, M Iba, C Kim, E Masliah |
Neurotherapeutics | 2020 |
|
Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology
C Zhang, RM Ötjengerdes, J Roewe, R Mejias, AL Marschall |
BioDrugs | 2020 |
|
From basic research to the clinic: innovative therapies for ALS and FTD in the pipeline
RM Liscic, A Alberici, NJ Cairns, M Romano, E Buratti |
Molecular Neurodegeneration | 2020 |
|
Therapeutic Approaches Targeting Protein Aggregation in Amyotrophic Lateral Sclerosis
R Malik, M Wiedau |
Frontiers in molecular neuroscience | 2020 |
|
Connecting RNA-Modifying Similarities of TDP-43, FUS, and SOD1 with MicroRNA Dysregulation Amidst A Renewed Network Perspective of Amyotrophic Lateral Sclerosis Proteinopathy
J Pham, M Keon, S Brennan, N Saksena |
International journal of molecular sciences | 2020 |
|
Withaferin-A Treatment Alleviates TAR DNA-Binding Protein-43 Pathology and Improves Cognitive Function in a Mouse Model of FTLD
S Kumar, D Phaneuf, JP Julien |
Neurotherapeutics | 2020 |
|
Engineered Extracellular Vesicles/Exosomes as a New Tool against Neurodegenerative Diseases
F Ferrantelli, C Chiozzini, P Leone, F Manfredi, M Federico |
Pharmaceutics | 2020 |
|
Recent advances in understanding amyotrophic lateral sclerosis and emerging therapies
LM Gittings, R Sattler |
2020 | |
|
Mitigation of ALS Pathology by Neuron-Specific Inhibition of Nuclear Factor Kappa B Signaling
K Dutta, SS Thammisetty, H Boutej, C Bareil, JP Julien |
The Journal of neuroscience : the official journal of the Society for Neuroscience | 2020 |
|
Uses for humanised mouse models in precision medicine for neurodegenerative disease
RR Nair, S Corrochano, S Gasco, C Tibbit, D Thompson, C Maduro, Z Ali, P Fratta, AA Arozena, TJ Cunningham, EM Fisher |
Mammalian Genome | 2019 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)